- Published on
Infectious Disease and Microbiology – Pneumonia
Pneumonia is defined as inflammation of the pulmonary parenchyma caused by an infectious agent. Pneumonia can be categorized according to the clinical setting in which it occurs. These categories include community-acquired pneumonia (CAP), which may be typical or atypical; pneumonia occurring in nursing-home residents; nosocomial pneumonia, including hospital-acquired and ventilator-associated pneumonia; pneumonia in immunocompromised hosts; and aspiration pneumonia.
Pneumonia is a major cause of morbidity and mortality worldwide. Approximately 4 million patients develop pneumonia annually in the United States. Community-acquired pneumonia affects about 12 per 1,000 inhabitants each year, with the highest incidence occurring at the extremes of age. Nosocomial pneumonia develops in approximately 0.5–1.5% of hospitalized patients and is particularly common among mechanically ventilated patients, especially those ventilated for prolonged periods. CAP is more common in children and adults older than 60 years.
Several important risk factors predispose individuals to pneumonia. These include alcoholism, aspiration, endotracheal intubation, immunosuppression, age greater than 65 years, hospitalization or nursing-home residence, particularly ICU stay, and underlying pulmonary diseases such as COPD and cystic fibrosis. Preventive measures include influenza and pneumococcal vaccination and minimizing the duration of endotracheal intubation whenever possible.
The pathophysiology of pneumonia involves activation of the host inflammatory response. Inflammatory mediators and chemokines released by macrophages and recruited neutrophils increase alveolar-capillary permeability, leading to alveolar filling with fluid and inflammatory cells. This results in infiltrates, rales, hemoptysis, hypoxemia, decreased lung compliance, and dyspnea. Increased respiratory drive, airway secretions, and infection-related bronchospasm further contribute to respiratory symptoms.
The etiology of pneumonia varies depending on the clinical setting. In community-acquired pneumonia, Streptococcus pneumoniae remains the most common pathogen. Other important organisms include Mycoplasma pneumoniae, Haemophilus influenzae, Chlamydia pneumoniae, and Staphylococcus aureus, particularly following influenza infection. Community-acquired MRSA strains may cause necrotizing or cavitary pneumonia. Viral pathogens such as hantaviruses, metapneumoviruses, and coronaviruses including SARS are also implicated. Polymicrobial infections are common, and Coxiella burnetii is an important atypical pathogen.
Nosocomial pneumonia is usually caused by gram-negative bacilli such as multidrug-resistant Pseudomonas, Klebsiella, Acinetobacter, and Xanthomonas species. MRSA is also common. Anaerobic bacteria and Legionella species may occasionally be involved, particularly in outbreaks related to contaminated water supplies.
In immunocompromised hosts, the responsible pathogens depend on the nature of the immune defect. Patients with humoral immune deficiencies are susceptible to S. pneumoniae, H. influenzae, S. aureus, and Neisseria species. Granulocyte dysfunction predisposes to gram-negative bacilli and Aspergillus infections. Cellular immune deficiencies increase susceptibility to fungal infections such as Pneumocystis jiroveci, Candida, and Cryptococcus; parasitic infections such as Toxoplasma and Strongyloides; mycobacterial infections; and viral infections including CMV and herpesviruses.
Patients with community-acquired pneumonia often report a recent upper respiratory tract infection. Symptoms commonly include fever, cough, sputum production, pleuritic chest pain, dyspnea, chills, sweats, fatigue, headache, myalgias, and arthralgias. Elderly patients may present atypically with confusion or altered mental status. Nosocomial pneumonia should be suspected in hospitalized patients after more than 48 hours of admission.
Physical examination commonly reveals tachypnea and tachycardia. Tactile fremitus may be increased or decreased. Percussion may demonstrate dullness due to consolidation or pleural fluid. Crackles, bronchial breath sounds, and pleural friction rubs may be present. Severe disease may manifest with hypotension or evidence of organ failure.
Initial laboratory evaluation includes complete blood count, pulse oximetry or arterial blood gas measurements, inflammatory markers such as C-reactive protein, and microbiologic cultures obtained from uncontaminated respiratory specimens. Chest radiography is the primary imaging study. If the initial chest radiograph is negative despite strong clinical suspicion, repeat imaging or chest CT may be necessary. Pneumatoceles suggest S. aureus infection, while upper-lobe cavitary lesions raise suspicion for tuberculosis. CT scanning may help identify post-obstructive pneumonia due to tumors or foreign bodies.
Additional diagnostic procedures may be required in severely ill or diagnostically challenging cases. These include bronchoscopy with bronchoalveolar lavage, transbronchial biopsy, lung biopsy, PCR testing, urinary antigen testing for S. pneumoniae and Legionella, and quantitative cultures. Concurrent endocarditis or meningitis should be excluded when clinically suspected.
The differential diagnosis includes infectious conditions such as bronchitis, empyema, lung abscess, and acute exacerbations of chronic bronchitis, as well as noninfectious conditions such as congestive heart failure, pulmonary embolism, lung cancer, and lymphoma.
Empiric antimicrobial therapy depends on the severity and setting of pneumonia. Outpatients with community-acquired pneumonia who are previously healthy and have not received recent antibiotics may be treated with azithromycin, clarithromycin, or doxycycline. Patients with comorbidities or recent antibiotic exposure should receive either a respiratory fluoroquinolone or a beta-lactam combined with a macrolide. Hospitalized non-ICU patients are generally treated with a respiratory fluoroquinolone or a beta-lactam plus macrolide. ICU patients require broader therapy with a beta-lactam plus azithromycin or a fluoroquinolone. If Pseudomonas is suspected, antipseudomonal agents are required, and linezolid should be added when CA-MRSA is suspected.
Treatment duration for CAP is generally at least 5 days, although many patients require 7–10 days of therapy. Longer treatment courses are necessary for infections due to Legionella, Coxiella burnetii, or S. aureus. Nosocomial pneumonia without MDR risk factors may be treated with ceftriaxone, respiratory fluoroquinolones, ampicillin-sulbactam, or ertapenem. Patients at risk for multidrug-resistant organisms require broad-spectrum antipseudomonal beta-lactams combined with aminoglycosides or fluoroquinolones and MRSA coverage with vancomycin or linezolid.
Supportive management includes adequate hydration, oxygen therapy, and assisted ventilation when necessary. Early administration of empiric antibiotics is critical and should ideally occur within 4 hours of hospital arrival. Severity assessment tools such as CURB-65 and the Pneumonia Severity Index help determine the need for hospitalization.
Patients should be monitored closely for oxygen saturation and clinical response. Discharge is appropriate once the patient is clinically improved, afebrile for at least 72 hours, hemodynamically stable, and able to tolerate oral antibiotics.
Radiographic abnormalities may take 4–12 weeks to resolve. Persistent or recurrent pneumonia should prompt evaluation for underlying malignancy or structural lung disease. Prognosis is generally excellent in outpatients with CAP, with mortality rates below 1%. Mortality rises to approximately 10% among hospitalized patients and is significantly higher in ventilator-associated pneumonia.
Complications include treatment failure due to resistant organisms, inadequate therapy, or noninfectious mimics; metastatic infection; complicated pleural effusions; and lung abscess formation.
Pneumonia is defined as inflammation of the pulmonary parenchyma caused by an infectious agent. Pneumonia can be categorized according to the clinical setting in which it occurs. These categories include community-acquired pneumonia (CAP), which may be typical or atypical; pneumonia occurring in nursing-home residents; nosocomial pneumonia, including hospital-acquired and ventilator-associated pneumonia; pneumonia in immunocompromised hosts; and aspiration pneumonia.
Pneumonia is a major cause of morbidity and mortality worldwide. Approximately 4 million patients develop pneumonia annually in the United States. Community-acquired pneumonia affects about 12 per 1,000 inhabitants each year, with the highest incidence occurring at the extremes of age. Nosocomial pneumonia develops in approximately 0.5–1.5% of hospitalized patients and is particularly common among mechanically ventilated patients, especially those ventilated for prolonged periods. CAP is more common in children and adults older than 60 years.
Several important risk factors predispose individuals to pneumonia. These include alcoholism, aspiration, endotracheal intubation, immunosuppression, age greater than 65 years, hospitalization or nursing-home residence, particularly ICU stay, and underlying pulmonary diseases such as COPD and cystic fibrosis. Preventive measures include influenza and pneumococcal vaccination and minimizing the duration of endotracheal intubation whenever possible.
The pathophysiology of pneumonia involves activation of the host inflammatory response. Inflammatory mediators and chemokines released by macrophages and recruited neutrophils increase alveolar-capillary permeability, leading to alveolar filling with fluid and inflammatory cells. This results in infiltrates, rales, hemoptysis, hypoxemia, decreased lung compliance, and dyspnea. Increased respiratory drive, airway secretions, and infection-related bronchospasm further contribute to respiratory symptoms.
The etiology of pneumonia varies depending on the clinical setting. In community-acquired pneumonia, Streptococcus pneumoniae remains the most common pathogen. Other important organisms include Mycoplasma pneumoniae, Haemophilus influenzae, Chlamydia pneumoniae, and Staphylococcus aureus, particularly following influenza infection. Community-acquired MRSA strains may cause necrotizing or cavitary pneumonia. Viral pathogens such as hantaviruses, metapneumoviruses, and coronaviruses including SARS are also implicated. Polymicrobial infections are common, and Coxiella burnetii is an important atypical pathogen.
Nosocomial pneumonia is usually caused by gram-negative bacilli such as multidrug-resistant Pseudomonas, Klebsiella, Acinetobacter, and Xanthomonas species. MRSA is also common. Anaerobic bacteria and Legionella species may occasionally be involved, particularly in outbreaks related to contaminated water supplies.
In immunocompromised hosts, the responsible pathogens depend on the nature of the immune defect. Patients with humoral immune deficiencies are susceptible to S. pneumoniae, H. influenzae, S. aureus, and Neisseria species. Granulocyte dysfunction predisposes to gram-negative bacilli and Aspergillus infections. Cellular immune deficiencies increase susceptibility to fungal infections such as Pneumocystis jiroveci, Candida, and Cryptococcus; parasitic infections such as Toxoplasma and Strongyloides; mycobacterial infections; and viral infections including CMV and herpesviruses.
Patients with community-acquired pneumonia often report a recent upper respiratory tract infection. Symptoms commonly include fever, cough, sputum production, pleuritic chest pain, dyspnea, chills, sweats, fatigue, headache, myalgias, and arthralgias. Elderly patients may present atypically with confusion or altered mental status. Nosocomial pneumonia should be suspected in hospitalized patients after more than 48 hours of admission.
Physical examination commonly reveals tachypnea and tachycardia. Tactile fremitus may be increased or decreased. Percussion may demonstrate dullness due to consolidation or pleural fluid. Crackles, bronchial breath sounds, and pleural friction rubs may be present. Severe disease may manifest with hypotension or evidence of organ failure.
Initial laboratory evaluation includes complete blood count, pulse oximetry or arterial blood gas measurements, inflammatory markers such as C-reactive protein, and microbiologic cultures obtained from uncontaminated respiratory specimens. Chest radiography is the primary imaging study. If the initial chest radiograph is negative despite strong clinical suspicion, repeat imaging or chest CT may be necessary. Pneumatoceles suggest S. aureus infection, while upper-lobe cavitary lesions raise suspicion for tuberculosis. CT scanning may help identify post-obstructive pneumonia due to tumors or foreign bodies.
Additional diagnostic procedures may be required in severely ill or diagnostically challenging cases. These include bronchoscopy with bronchoalveolar lavage, transbronchial biopsy, lung biopsy, PCR testing, urinary antigen testing for S. pneumoniae and Legionella, and quantitative cultures. Concurrent endocarditis or meningitis should be excluded when clinically suspected.
The differential diagnosis includes infectious conditions such as bronchitis, empyema, lung abscess, and acute exacerbations of chronic bronchitis, as well as noninfectious conditions such as congestive heart failure, pulmonary embolism, lung cancer, and lymphoma.
Empiric antimicrobial therapy depends on the severity and setting of pneumonia. Outpatients with community-acquired pneumonia who are previously healthy and have not received recent antibiotics may be treated with azithromycin, clarithromycin, or doxycycline. Patients with comorbidities or recent antibiotic exposure should receive either a respiratory fluoroquinolone or a beta-lactam combined with a macrolide. Hospitalized non-ICU patients are generally treated with a respiratory fluoroquinolone or a beta-lactam plus macrolide. ICU patients require broader therapy with a beta-lactam plus azithromycin or a fluoroquinolone. If Pseudomonas is suspected, antipseudomonal agents are required, and linezolid should be added when CA-MRSA is suspected.
Treatment duration for CAP is generally at least 5 days, although many patients require 7–10 days of therapy. Longer treatment courses are necessary for infections due to Legionella, Coxiella burnetii, or S. aureus. Nosocomial pneumonia without MDR risk factors may be treated with ceftriaxone, respiratory fluoroquinolones, ampicillin-sulbactam, or ertapenem. Patients at risk for multidrug-resistant organisms require broad-spectrum antipseudomonal beta-lactams combined with aminoglycosides or fluoroquinolones and MRSA coverage with vancomycin or linezolid.
Supportive management includes adequate hydration, oxygen therapy, and assisted ventilation when necessary. Early administration of empiric antibiotics is critical and should ideally occur within 4 hours of hospital arrival. Severity assessment tools such as CURB-65 and the Pneumonia Severity Index help determine the need for hospitalization.
Patients should be monitored closely for oxygen saturation and clinical response. Discharge is appropriate once the patient is clinically improved, afebrile for at least 72 hours, hemodynamically stable, and able to tolerate oral antibiotics.
Radiographic abnormalities may take 4–12 weeks to resolve. Persistent or recurrent pneumonia should prompt evaluation for underlying malignancy or structural lung disease. Prognosis is generally excellent in outpatients with CAP, with mortality rates below 1%. Mortality rises to approximately 10% among hospitalized patients and is significantly higher in ventilator-associated pneumonia.
Complications include treatment failure due to resistant organisms, inadequate therapy, or noninfectious mimics; metastatic infection; complicated pleural effusions; and lung abscess formation.
- Published on
Infectious Disease and Microbiology -Pneumocystis jiroveci (Carinii) Infection
Pneumocystis jiroveci is an opportunistic fungal pathogen whose natural habitat is the lung. It is an important cause of pneumonia in immunocompromised patients, especially individuals with HIV/AIDS. The disease is commonly referred to as Pneumocystis pneumonia (PCP). Although formerly known as Pneumocystis carinii, the organism infecting humans is now correctly termed Pneumocystis jiroveci. Despite advances in prophylaxis and antiretroviral therapy, PCP remains one of the most common opportunistic infections in HIV-infected patients.
The incidence of PCP has decreased substantially because of routine prophylaxis and improved HIV management. However, it still occurs frequently among patients with advanced immunosuppression. PCP has also been reported in patients receiving immunomodulatory therapies such as infliximab and etanercept. Extrapulmonary disease is uncommon, occurring in fewer than 3% of cases. Internationally, the reported incidence is considered low, although this is likely due to underdiagnosis. PCP is particularly important in HIV-infected infants, among whom it is responsible for a large proportion of pneumonia cases.
Major risk factors include HIV/AIDS with CD4 counts below 200/mm³, malignancy, long-term corticosteroid or immunosuppressive therapy, primary immunodeficiency syndromes, tobacco use, and severe malnutrition. Patients with organ transplants, hematologic malignancies, and severe combined immunodeficiency are also at increased risk. Because of these risks, prophylaxis is recommended for high-risk HIV-infected individuals and certain other immunocompromised populations.
Primary prophylaxis is indicated in HIV-infected patients with CD4 counts below 200/mm³ or in those with oropharyngeal candidiasis regardless of CD4 count. The preferred prophylactic regimen is one double-strength tablet of trimethoprim-sulfamethoxazole daily. Alternative regimens include reduced-dose TMP-SMX, dapsone-based regimens, nebulized pentamidine, or pyrimethamine combinations. Secondary prophylaxis is recommended for all patients recovering from PCP until immune reconstitution occurs.
Infection with P. jiroveci usually occurs early in childhood, and many healthy individuals harbor the organism in their lungs without disease. In immunocompromised hosts, defective cellular immunity—especially impaired CD4 T-cell function—prevents effective clearance of the organism. Activated macrophages become unable to eliminate the fungus, resulting in increased alveolar-capillary permeability and impaired gas exchange. This process produces hypoxemia, respiratory alkalosis, and diffuse interstitial pneumonia.
Patients usually present with nonspecific symptoms such as progressive exertional dyspnea, fever, dry cough, chest discomfort, chills, and weight loss. In HIV-infected individuals, the illness often develops gradually over days to weeks, whereas in non-HIV immunocompromised patients the disease may progress rapidly and severely. Hemoptysis is uncommon but may occur.
On physical examination, patients commonly have tachypnea, fever, and tachycardia. Pulmonary examination may be surprisingly normal in up to half of patients despite significant hypoxemia. Children with severe disease may exhibit cyanosis, nasal flaring, and intercostal retractions. Rare extrapulmonary manifestations can involve the central nervous system, thyroid, gastrointestinal tract, lymph nodes, eyes, and bone marrow.
Laboratory findings are nonspecific. Elevated lactate dehydrogenase (LDH) levels are common but not diagnostic. Serum β-D-glucan levels are frequently elevated. Arterial blood gas analysis typically demonstrates hypoxemia, respiratory alkalosis, and an increased alveolar–arterial oxygen gradient. Disease severity is often classified according to the degree of alveolar–arterial gradient elevation.
Chest radiography classically demonstrates bilateral diffuse perihilar infiltrates, although early disease may show a normal chest x-ray. Chest CT scanning is more sensitive and commonly reveals diffuse bilateral ground-glass opacities. Patients receiving aerosolized pentamidine prophylaxis may show upper-lobe infiltrates and are at increased risk for pneumothorax.
Definitive diagnosis requires identification of the organism in respiratory specimens. Fiberoptic bronchoscopy with bronchoalveolar lavage remains the diagnostic standard. Induced sputum may be used but has variable sensitivity. Histopathologic stains such as methenamine silver, toluidine blue, Giemsa, and immunofluorescent stains are used to identify cysts and trophozoites. More invasive procedures such as transbronchial biopsy or open-lung biopsy are reserved for difficult cases.
The differential diagnosis includes other causes of diffuse pneumonia and respiratory failure, including tuberculosis, cytomegalovirus pneumonia, viral pneumonias, Legionella infection, fungal pneumonias, pulmonary embolism, ARDS, congestive heart failure, and pulmonary involvement by Kaposi sarcoma or lymphoma.
Trimethoprim-sulfamethoxazole (TMP-SMX) is the treatment of choice for PCP. The recommended dose is 15–20 mg/kg/day of the trimethoprim component, administered orally or intravenously in divided doses. Treatment duration is 21 days in HIV-infected patients and 14 days in non-HIV patients. Clinical improvement usually occurs within several days, although clinicians should wait at least 4–8 days before concluding treatment failure.
Adjunctive corticosteroids significantly improve survival in patients with moderate to severe disease, particularly in HIV-associated PCP. Steroids are indicated in patients with a PaO₂ below 70 mm Hg or an alveolar–arterial gradient greater than or equal to 35 mm Hg. Prednisone is typically administered in tapering doses over 21 days and should be started within 72 hours of initiating antimicrobial therapy.
Alternative therapies are used when TMP-SMX cannot be tolerated or when treatment failure occurs. Intravenous pentamidine is an effective alternative but may cause significant toxicities including hypotension, arrhythmias, pancreatitis, dysglycemia, renal dysfunction, electrolyte abnormalities, and neutropenia. Other options include clindamycin plus primaquine, atovaquone, or trimethoprim plus dapsone. Primaquine should be avoided in patients with glucose-6-phosphate dehydrogenase deficiency.
Patients require close monitoring for clinical response, oxygenation status, and medication-related adverse effects. Complications include progressive respiratory failure, pneumothorax, concurrent pulmonary infections, and death. Mortality rates are approximately 10–20% among HIV-infected patients but may reach 30–50% in non-HIV immunocompromised individuals, largely due to delayed diagnosis and treatment. Early recognition and prompt therapy remain essential for improving outcomes.
Pneumocystis jiroveci is an opportunistic fungal pathogen whose natural habitat is the lung. It is an important cause of pneumonia in immunocompromised patients, especially individuals with HIV/AIDS. The disease is commonly referred to as Pneumocystis pneumonia (PCP). Although formerly known as Pneumocystis carinii, the organism infecting humans is now correctly termed Pneumocystis jiroveci. Despite advances in prophylaxis and antiretroviral therapy, PCP remains one of the most common opportunistic infections in HIV-infected patients.
The incidence of PCP has decreased substantially because of routine prophylaxis and improved HIV management. However, it still occurs frequently among patients with advanced immunosuppression. PCP has also been reported in patients receiving immunomodulatory therapies such as infliximab and etanercept. Extrapulmonary disease is uncommon, occurring in fewer than 3% of cases. Internationally, the reported incidence is considered low, although this is likely due to underdiagnosis. PCP is particularly important in HIV-infected infants, among whom it is responsible for a large proportion of pneumonia cases.
Major risk factors include HIV/AIDS with CD4 counts below 200/mm³, malignancy, long-term corticosteroid or immunosuppressive therapy, primary immunodeficiency syndromes, tobacco use, and severe malnutrition. Patients with organ transplants, hematologic malignancies, and severe combined immunodeficiency are also at increased risk. Because of these risks, prophylaxis is recommended for high-risk HIV-infected individuals and certain other immunocompromised populations.
Primary prophylaxis is indicated in HIV-infected patients with CD4 counts below 200/mm³ or in those with oropharyngeal candidiasis regardless of CD4 count. The preferred prophylactic regimen is one double-strength tablet of trimethoprim-sulfamethoxazole daily. Alternative regimens include reduced-dose TMP-SMX, dapsone-based regimens, nebulized pentamidine, or pyrimethamine combinations. Secondary prophylaxis is recommended for all patients recovering from PCP until immune reconstitution occurs.
Infection with P. jiroveci usually occurs early in childhood, and many healthy individuals harbor the organism in their lungs without disease. In immunocompromised hosts, defective cellular immunity—especially impaired CD4 T-cell function—prevents effective clearance of the organism. Activated macrophages become unable to eliminate the fungus, resulting in increased alveolar-capillary permeability and impaired gas exchange. This process produces hypoxemia, respiratory alkalosis, and diffuse interstitial pneumonia.
Patients usually present with nonspecific symptoms such as progressive exertional dyspnea, fever, dry cough, chest discomfort, chills, and weight loss. In HIV-infected individuals, the illness often develops gradually over days to weeks, whereas in non-HIV immunocompromised patients the disease may progress rapidly and severely. Hemoptysis is uncommon but may occur.
On physical examination, patients commonly have tachypnea, fever, and tachycardia. Pulmonary examination may be surprisingly normal in up to half of patients despite significant hypoxemia. Children with severe disease may exhibit cyanosis, nasal flaring, and intercostal retractions. Rare extrapulmonary manifestations can involve the central nervous system, thyroid, gastrointestinal tract, lymph nodes, eyes, and bone marrow.
Laboratory findings are nonspecific. Elevated lactate dehydrogenase (LDH) levels are common but not diagnostic. Serum β-D-glucan levels are frequently elevated. Arterial blood gas analysis typically demonstrates hypoxemia, respiratory alkalosis, and an increased alveolar–arterial oxygen gradient. Disease severity is often classified according to the degree of alveolar–arterial gradient elevation.
Chest radiography classically demonstrates bilateral diffuse perihilar infiltrates, although early disease may show a normal chest x-ray. Chest CT scanning is more sensitive and commonly reveals diffuse bilateral ground-glass opacities. Patients receiving aerosolized pentamidine prophylaxis may show upper-lobe infiltrates and are at increased risk for pneumothorax.
Definitive diagnosis requires identification of the organism in respiratory specimens. Fiberoptic bronchoscopy with bronchoalveolar lavage remains the diagnostic standard. Induced sputum may be used but has variable sensitivity. Histopathologic stains such as methenamine silver, toluidine blue, Giemsa, and immunofluorescent stains are used to identify cysts and trophozoites. More invasive procedures such as transbronchial biopsy or open-lung biopsy are reserved for difficult cases.
The differential diagnosis includes other causes of diffuse pneumonia and respiratory failure, including tuberculosis, cytomegalovirus pneumonia, viral pneumonias, Legionella infection, fungal pneumonias, pulmonary embolism, ARDS, congestive heart failure, and pulmonary involvement by Kaposi sarcoma or lymphoma.
Trimethoprim-sulfamethoxazole (TMP-SMX) is the treatment of choice for PCP. The recommended dose is 15–20 mg/kg/day of the trimethoprim component, administered orally or intravenously in divided doses. Treatment duration is 21 days in HIV-infected patients and 14 days in non-HIV patients. Clinical improvement usually occurs within several days, although clinicians should wait at least 4–8 days before concluding treatment failure.
Adjunctive corticosteroids significantly improve survival in patients with moderate to severe disease, particularly in HIV-associated PCP. Steroids are indicated in patients with a PaO₂ below 70 mm Hg or an alveolar–arterial gradient greater than or equal to 35 mm Hg. Prednisone is typically administered in tapering doses over 21 days and should be started within 72 hours of initiating antimicrobial therapy.
Alternative therapies are used when TMP-SMX cannot be tolerated or when treatment failure occurs. Intravenous pentamidine is an effective alternative but may cause significant toxicities including hypotension, arrhythmias, pancreatitis, dysglycemia, renal dysfunction, electrolyte abnormalities, and neutropenia. Other options include clindamycin plus primaquine, atovaquone, or trimethoprim plus dapsone. Primaquine should be avoided in patients with glucose-6-phosphate dehydrogenase deficiency.
Patients require close monitoring for clinical response, oxygenation status, and medication-related adverse effects. Complications include progressive respiratory failure, pneumothorax, concurrent pulmonary infections, and death. Mortality rates are approximately 10–20% among HIV-infected patients but may reach 30–50% in non-HIV immunocompromised individuals, largely due to delayed diagnosis and treatment. Early recognition and prompt therapy remain essential for improving outcomes.
- Published on
Infectious disease and microbiology – Plague
Plague is a severe zoonotic infection caused by Yersinia pestis, a gram-negative aerobic coccobacillus belonging to the Enterobacteriaceae family. Historically, plague caused the devastating “Black Death” pandemics of the Middle Ages. Clinically, the disease may present as bubonic, septicemic, pneumonic, meningeal, or pharyngeal plague.
Plague remains endemic in several regions of the world, especially in parts of Africa, Asia, and the Americas. Between 1998 and 2003, more than 38,000 cases and nearly 3,000 deaths were reported globally. In the United States, most cases occur in the southwestern states, particularly New Mexico, Arizona, and Colorado.
Major risk factors include residence or travel in endemic areas, poor rodent control, exposure to rodents or rodent predators, occupational exposure among veterinarians and laboratory workers, close contact with infected animals, and inadequate flea control in domestic animals.
The disease is maintained in nature through an enzootic cycle involving rodents and fleas. Humans are accidental hosts and do not contribute significantly to maintaining transmission. Infection occurs through:
Clinical Forms
Bubonic plague
The most common presentation.
Symptoms
Septicemic plague
May occur primarily or as progression from bubonic disease.
Features
Pneumonic plague
The most dangerous and contagious form.
Symptoms
Meningeal plague
Rare complication due to CNS seeding during bacteremia.
Features
Diagnosis
Laboratory abnormalities may include:
Special culture media include:
Chest radiography in pneumonic plague may show:
Treatment
First-line therapy
Aminoglycosides
Alternative agents
Supportive Care
Management may also require:
Infection Control
Pneumonic plague
Requires:
Standard precautions are usually sufficient.
Healthcare and laboratory personnel should be informed immediately if plague is suspected because Y. pestis is considered a potential bioterrorism agent owing to its high virulence and aerosol transmissibility.
Prognosis and Complications
Untreated plague has mortality rates approaching 50%, while untreated pneumonic plague is almost universally fatal.
Complications include:
Plague is a severe zoonotic infection caused by Yersinia pestis, a gram-negative aerobic coccobacillus belonging to the Enterobacteriaceae family. Historically, plague caused the devastating “Black Death” pandemics of the Middle Ages. Clinically, the disease may present as bubonic, septicemic, pneumonic, meningeal, or pharyngeal plague.
Plague remains endemic in several regions of the world, especially in parts of Africa, Asia, and the Americas. Between 1998 and 2003, more than 38,000 cases and nearly 3,000 deaths were reported globally. In the United States, most cases occur in the southwestern states, particularly New Mexico, Arizona, and Colorado.
Major risk factors include residence or travel in endemic areas, poor rodent control, exposure to rodents or rodent predators, occupational exposure among veterinarians and laboratory workers, close contact with infected animals, and inadequate flea control in domestic animals.
The disease is maintained in nature through an enzootic cycle involving rodents and fleas. Humans are accidental hosts and do not contribute significantly to maintaining transmission. Infection occurs through:
- Bite of an infected flea
- Direct contact with infected animals or carcasses
- Inhalation of respiratory droplets from pneumonic plague patients or infected animals
Clinical Forms
Bubonic plague
The most common presentation.
Symptoms
- Sudden fever and chills
- Headache and weakness
- Painful swollen lymph nodes (“buboes”) appearing within 24 hours
- Large, tender, erythematous lymph nodes
- Usually inguinal or femoral nodes
- Buboes may ulcerate
- Flea-bite papules or pustules may be present
Septicemic plague
May occur primarily or as progression from bubonic disease.
Features
- Severe sepsis and toxic appearance
- Hypotension
- Gastrointestinal symptoms
- Disseminated intravascular coagulation
- Acral gangrene (“black death”)
- Buboes may be absent
Pneumonic plague
The most dangerous and contagious form.
Symptoms
- Rapidly progressive pneumonia
- Productive cough with bloody sputum
- Pleuritic chest pain
- Severe respiratory distress and hypoxia
Meningeal plague
Rare complication due to CNS seeding during bacteremia.
Features
- Fever
- Headache
- Neck stiffness
Diagnosis
Laboratory abnormalities may include:
- Leukocytosis
- Thrombocytopenia
- Elevated liver enzymes
- Elevated creatinine and BUN
- Disseminated intravascular coagulation in severe disease
- Bubo aspirates
- Sputum
- Throat swabs
- CSF
- Skin swabs
Special culture media include:
- MacConkey agar
- Chocolate agar
- Sheep blood agar
- Brain-heart infusion broth
Chest radiography in pneumonic plague may show:
- Lobar or patchy infiltrates
- Cavitation
- Pleural effusions
- ARDS-like diffuse opacities
Treatment
First-line therapy
Aminoglycosides
- Streptomycin 30 mg/kg/day IM in 2 divided doses
- Gentamicin 2.5 mg/kg IM every 12 hours
Alternative agents
- Doxycycline
- Tetracycline
- Chloramphenicol
- TMP-SMX
Supportive Care
Management may also require:
- Intravenous fluids
- Analgesics and antipyretics
- Intensive care support for septic shock or respiratory failure
Infection Control
Pneumonic plague
Requires:
- Respiratory droplet isolation
- Hospital admission
- Immediate antimicrobial treatment
Standard precautions are usually sufficient.
Healthcare and laboratory personnel should be informed immediately if plague is suspected because Y. pestis is considered a potential bioterrorism agent owing to its high virulence and aerosol transmissibility.
Prognosis and Complications
Untreated plague has mortality rates approaching 50%, while untreated pneumonic plague is almost universally fatal.
Complications include:
- Pneumonia
- Septic shock
- Multiorgan failure
- Respiratory failure
- Disseminated intravascular coagulation
- Secondary bacterial superinfection of buboes
- Published on
Infectious disease and microbiology – Pilonidal abscess
A pilonidal abscess is an infection of a pilonidal cyst, usually located in the postanal or sacrococcygeal region within the natal cleft. Pilonidal disease is now considered an acquired condition rather than congenital and ranges from asymptomatic pits to painful abscesses and chronic draining sinuses.
The disease is relatively common, with approximately 70,000 new cases annually in the United States. It occurs most often in young adults between 18 and 30 years of age and is significantly more common in males than females, with a male-to-female ratio of about 3:1. Higher rates are reported in Mediterranean populations, whereas the disease is relatively uncommon in East Asia, Oceania, and sub-Saharan Africa.
Several risk factors contribute to pilonidal disease, including male gender, obesity, excessive body hair, poor hygiene, and a deep natal cleft. Although prevention is difficult, maintaining good perianal hygiene and regular hair removal may reduce recurrence and progression.
The pathogenesis involves the formation of a hair follicle pit in the natal cleft, which enlarges and fills with keratin and debris. Hair penetration into the skin triggers a foreign body inflammatory reaction, leading to infection of the surrounding subcutaneous tissue. Chronic disease may result in sinus tract formation, with the direction of hair insertion influencing the tract pattern.
The exact microbial causes are variable, but infections are usually polymicrobial and involve organisms from the skin flora and bowel flora, including anaerobic bacteria.
Clinically, patients typically present with a painful, tender, warm, fluctuant swelling in the sacrococcygeal area during acute infection. Chronic disease may produce persistent or intermittent drainage from midline pits or sinus tracts, with symptoms waxing and waning over weeks.
Diagnosis is mainly clinical and based on physical examination. Characteristic findings include midline pits in the gluteal cleft, usually located approximately 5 cm above the anus. Acute abscesses, chronic sinus tracts, or minimal inflammation may be present. An anorectal examination is important to exclude other conditions.
The differential diagnosis includes both infectious and noninfectious disorders such as perianal abscess, hidradenitis suppurativa, necrotizing fasciitis, furunculosis, herpes simplex infection, syphilis, tuberculosis, anal fistulas, Crohn disease, coccygodynia, and radiation proctitis.
Management depends on the severity and chronicity of disease. Antibiotics alone have a limited role but may be useful in patients with associated cellulitis, systemic illness, or immunosuppression. When used, therapy should include anaerobic coverage. Meticulous local hygiene and hair removal are recommended as supportive measures.
For minimally symptomatic disease, nonsurgical therapies such as phenol or fibrin glue injection combined with hygiene and hair control may be attempted. However, the mainstay of treatment for most acute or chronic cases is surgical management. Limited excision with an off-midline incision and removal of the sinus pits is often sufficient and allows quicker recovery with acceptable recurrence rates. More extensive recurrent or complicated disease may require wide excision and reconstruction with flattening of the natal cleft, although this approach carries higher morbidity.
The overall prognosis is excellent, though recurrence is relatively common and may necessitate repeat or more extensive surgery. Rare complications include large abscesses leading to sepsis and shock, and in very long-standing untreated disease, the development of carcinoma arising from a chronic pilonidal sinus.
A pilonidal abscess is an infection of a pilonidal cyst, usually located in the postanal or sacrococcygeal region within the natal cleft. Pilonidal disease is now considered an acquired condition rather than congenital and ranges from asymptomatic pits to painful abscesses and chronic draining sinuses.
The disease is relatively common, with approximately 70,000 new cases annually in the United States. It occurs most often in young adults between 18 and 30 years of age and is significantly more common in males than females, with a male-to-female ratio of about 3:1. Higher rates are reported in Mediterranean populations, whereas the disease is relatively uncommon in East Asia, Oceania, and sub-Saharan Africa.
Several risk factors contribute to pilonidal disease, including male gender, obesity, excessive body hair, poor hygiene, and a deep natal cleft. Although prevention is difficult, maintaining good perianal hygiene and regular hair removal may reduce recurrence and progression.
The pathogenesis involves the formation of a hair follicle pit in the natal cleft, which enlarges and fills with keratin and debris. Hair penetration into the skin triggers a foreign body inflammatory reaction, leading to infection of the surrounding subcutaneous tissue. Chronic disease may result in sinus tract formation, with the direction of hair insertion influencing the tract pattern.
The exact microbial causes are variable, but infections are usually polymicrobial and involve organisms from the skin flora and bowel flora, including anaerobic bacteria.
Clinically, patients typically present with a painful, tender, warm, fluctuant swelling in the sacrococcygeal area during acute infection. Chronic disease may produce persistent or intermittent drainage from midline pits or sinus tracts, with symptoms waxing and waning over weeks.
Diagnosis is mainly clinical and based on physical examination. Characteristic findings include midline pits in the gluteal cleft, usually located approximately 5 cm above the anus. Acute abscesses, chronic sinus tracts, or minimal inflammation may be present. An anorectal examination is important to exclude other conditions.
The differential diagnosis includes both infectious and noninfectious disorders such as perianal abscess, hidradenitis suppurativa, necrotizing fasciitis, furunculosis, herpes simplex infection, syphilis, tuberculosis, anal fistulas, Crohn disease, coccygodynia, and radiation proctitis.
Management depends on the severity and chronicity of disease. Antibiotics alone have a limited role but may be useful in patients with associated cellulitis, systemic illness, or immunosuppression. When used, therapy should include anaerobic coverage. Meticulous local hygiene and hair removal are recommended as supportive measures.
For minimally symptomatic disease, nonsurgical therapies such as phenol or fibrin glue injection combined with hygiene and hair control may be attempted. However, the mainstay of treatment for most acute or chronic cases is surgical management. Limited excision with an off-midline incision and removal of the sinus pits is often sufficient and allows quicker recovery with acceptable recurrence rates. More extensive recurrent or complicated disease may require wide excision and reconstruction with flattening of the natal cleft, although this approach carries higher morbidity.
The overall prognosis is excellent, though recurrence is relatively common and may necessitate repeat or more extensive surgery. Rare complications include large abscesses leading to sepsis and shock, and in very long-standing untreated disease, the development of carcinoma arising from a chronic pilonidal sinus.
- Published on
Toxicology – Isoniazid (INH) Toxicity
Source
Isoniazid (INH) is a first-line antitubercular medication used to treat both latent and active tuberculosis. It is structurally related to pyridoxine (vitamin B6).
Typical Presentation
Acute overdose classically presents with severe, refractory seizures and metabolic acidosis. Children are particularly vulnerable, and toxicity may occur rapidly after ingestion. Chronic use is associated with liver injury and neurological complications.
Clinical Features
Acute Toxicity
Symptoms may begin within 30 minutes of ingestion and include:
Long-term exposure may cause:
INH interferes with pyridoxine (vitamin B6) metabolism, impairing pyridoxine-dependent enzymatic pathways. This leads to depletion of GABA and excess glutamate activity, predisposing patients to seizures.
Management
Treatment focuses on seizure control, airway stabilization, and reversal of vitamin B6 depletion:
Key Points
Source
Isoniazid (INH) is a first-line antitubercular medication used to treat both latent and active tuberculosis. It is structurally related to pyridoxine (vitamin B6).
Typical Presentation
Acute overdose classically presents with severe, refractory seizures and metabolic acidosis. Children are particularly vulnerable, and toxicity may occur rapidly after ingestion. Chronic use is associated with liver injury and neurological complications.
Clinical Features
Acute Toxicity
Symptoms may begin within 30 minutes of ingestion and include:
- Refractory seizures
- Altered mental status or coma
- Vomiting
- Slurred speech
- Hyperreflexia or hyporeflexia
- Tachycardia
- Oliguria
- High anion gap metabolic acidosis
- Elevated lactate levels
Long-term exposure may cause:
- Elevated liver enzymes and hepatitis
- Hepatocellular necrosis
- Peripheral neuropathy
- Optic neuritis
- Vitamin B6 deficiency
- Autoimmune manifestations (e.g., anemia, arthritis, eosinophilia)
INH interferes with pyridoxine (vitamin B6) metabolism, impairing pyridoxine-dependent enzymatic pathways. This leads to depletion of GABA and excess glutamate activity, predisposing patients to seizures.
Management
Treatment focuses on seizure control, airway stabilization, and reversal of vitamin B6 depletion:
- Benzodiazepines, propofol, or barbiturates for seizures
- Sodium bicarbonate for severe acidosis
- Supportive airway and hemodynamic management
- Ideally given gram-for-gram equal to the amount of INH ingested
- If the dose is unknown, an initial 5 g IV dose is recommended and may be repeated if seizures continue
Key Points
- Consider INH poisoning in patients with seizures unresponsive to standard anticonvulsants.
- Refractory seizures plus metabolic acidosis is highly suggestive.
- Pyridoxine is the definitive antidote.
- Chronic therapy may cause neuropathy and hepatotoxicity.
- Published on
Toxicology – Warfarin & Superwarfarin Toxicity
Source
Warfarin is a commonly prescribed anticoagulant that works by blocking vitamin K–dependent clotting pathways. “Superwarfarins” are long-acting anticoagulant rodenticides that include agents such as brodifacoum, bromadiolone, difenacoum, and chlorophacinone. These compounds are far more potent and longer lasting than standard warfarin.
Typical Presentation
Patients may present with unexplained bleeding after accidental, intentional, or occupational exposure. Children may ingest rodenticide pellets, while adults often present later once bleeding symptoms appear.
Clinical Features
Both warfarin and superwarfarins impair blood clotting, leading to elevated PT/INR levels and bleeding manifestations such as:
Mechanism of Action
These agents inhibit vitamin K epoxide reductase, preventing regeneration of active vitamin K. This decreases production of clotting factors II, VII, IX, and X, resulting in impaired coagulation.
Management
Treatment depends on severity and timing of exposure:
Source
Warfarin is a commonly prescribed anticoagulant that works by blocking vitamin K–dependent clotting pathways. “Superwarfarins” are long-acting anticoagulant rodenticides that include agents such as brodifacoum, bromadiolone, difenacoum, and chlorophacinone. These compounds are far more potent and longer lasting than standard warfarin.
Typical Presentation
Patients may present with unexplained bleeding after accidental, intentional, or occupational exposure. Children may ingest rodenticide pellets, while adults often present later once bleeding symptoms appear.
Clinical Features
Both warfarin and superwarfarins impair blood clotting, leading to elevated PT/INR levels and bleeding manifestations such as:
- Easy bruising and ecchymoses
- Nosebleeds and gum bleeding
- Bloody stools or vomit
- Blood in urine
- Heavy menstrual bleeding
- Pulmonary or internal hemorrhage
Mechanism of Action
These agents inhibit vitamin K epoxide reductase, preventing regeneration of active vitamin K. This decreases production of clotting factors II, VII, IX, and X, resulting in impaired coagulation.
Management
Treatment depends on severity and timing of exposure:
- Activated charcoal and whole bowel irrigation may be considered after large recent ingestions.
- Coagulation studies (especially PT/INR) should be closely monitored.
- Active bleeding is treated with vitamin K and fresh frozen plasma (FFP) or clotting factor concentrates.
- Superwarfarin poisoning may require high-dose oral vitamin K therapy for weeks to months to maintain a normal INR.
- Superwarfarins have much longer effects than prescription warfarin.
- Elevated PT/INR is a hallmark laboratory finding.
- Severe bleeding may occur spontaneously.
- Long-term vitamin K therapy is often required after rodenticide exposure.
- Published on
91. Toxicology – Colchicine Toxicity
Source
Colchicine is a medication commonly prescribed for gout, pericarditis, and familial Mediterranean fever. It is derived from the autumn crocus plant (Colchicum autumnale) and has a narrow therapeutic index.
Typical Presentation
Patients usually present after an overdose with severe gastrointestinal symptoms that may initially resemble infectious gastroenteritis. Toxicity can rapidly progress to multiorgan failure over the following days.
Clinical Features
Colchicine poisoning classically progresses through three stages:
Colchicine disrupts microtubule formation and inhibits mitosis, impairing rapidly dividing cells such as those in the gastrointestinal tract and bone marrow.
Management
Treatment is primarily supportive and includes:
Key Points
Source
Colchicine is a medication commonly prescribed for gout, pericarditis, and familial Mediterranean fever. It is derived from the autumn crocus plant (Colchicum autumnale) and has a narrow therapeutic index.
Typical Presentation
Patients usually present after an overdose with severe gastrointestinal symptoms that may initially resemble infectious gastroenteritis. Toxicity can rapidly progress to multiorgan failure over the following days.
Clinical Features
Colchicine poisoning classically progresses through three stages:
- Phase 1 (within hours): Severe nausea, vomiting, diarrhea, abdominal pain, dehydration, tachycardia, hypotension, and early kidney injury.
- Phase 2 (days later): Multisystem toxicity develops, including bone marrow suppression, low white blood cell counts, kidney and liver failure, rhabdomyolysis, pulmonary edema, ARDS, cardiovascular collapse, and pancytopenia.
- Phase 3 (recovery phase): Survivors may later develop hair loss (alopecia) and ascending peripheral neuropathy.
Colchicine disrupts microtubule formation and inhibits mitosis, impairing rapidly dividing cells such as those in the gastrointestinal tract and bone marrow.
Management
Treatment is primarily supportive and includes:
- Aggressive IV fluid resuscitation
- Airway and hemodynamic support
- Antiemetics for severe GI symptoms
- Activated charcoal to reduce enterohepatic recirculation
Key Points
- Early symptoms may mimic viral gastroenteritis.
- Toxicity can progress rapidly to fatal multiorgan failure.
- Bone marrow suppression is a major complication.
- Dialysis is not useful in colchicine overdose.
- Published on
Toxicology – Ricin Poisoning
Source
Ricin is a highly toxic protein derived from the seeds of the castor oil plant (Ricinus communis). It has been studied and misused due to its potent biological effects.
Typical Presentation
Exposure may occur through ingestion, inhalation, or injection. A well-known historical case involved a targeted poisoning where symptoms developed after a seemingly minor skin puncture. Patients often initially appear with nonspecific, flu-like complaints before rapidly deteriorating.
Clinical Features
When ingested, ricin primarily affects the gastrointestinal system, causing severe abdominal pain, vomiting, diarrhea, and potentially bleeding, which can lead to organ damage. Inhalation exposure results in progressive respiratory symptoms, including cough and shortness of breath, which may advance to respiratory failure. Systemic symptoms such as fever and weakness are also common.
Mechanism of Action
Ricin exerts its toxicity by blocking protein synthesis within cells, leading to widespread cellular damage and organ failure.
Management
There is no specific antidote. Treatment is supportive and focuses on maintaining vital functions, including respiratory and circulatory support as needed.
Key Points
Source
Ricin is a highly toxic protein derived from the seeds of the castor oil plant (Ricinus communis). It has been studied and misused due to its potent biological effects.
Typical Presentation
Exposure may occur through ingestion, inhalation, or injection. A well-known historical case involved a targeted poisoning where symptoms developed after a seemingly minor skin puncture. Patients often initially appear with nonspecific, flu-like complaints before rapidly deteriorating.
Clinical Features
When ingested, ricin primarily affects the gastrointestinal system, causing severe abdominal pain, vomiting, diarrhea, and potentially bleeding, which can lead to organ damage. Inhalation exposure results in progressive respiratory symptoms, including cough and shortness of breath, which may advance to respiratory failure. Systemic symptoms such as fever and weakness are also common.
Mechanism of Action
Ricin exerts its toxicity by blocking protein synthesis within cells, leading to widespread cellular damage and organ failure.
Management
There is no specific antidote. Treatment is supportive and focuses on maintaining vital functions, including respiratory and circulatory support as needed.
Key Points
- Symptoms vary depending on the route of exposure.
- Effects may initially resemble common illnesses, delaying recognition.
- Intact seeds are less harmful if swallowed whole, but chewing releases the toxin and increases risk.
- Published on
Toxicology – Radiation Exposure and Poisoning
Source
Radiation exposure can occur in medical settings (e.g., imaging and cancer therapy), research environments, industrial operations, and nuclear incidents. Radioactive materials are also used in energy production and, in rare cases, weaponized forms.
Typical Presentation
Exposure may be accidental, occupational, or intentional. Large-scale incidents (such as nuclear accidents) or isolated exposures (such as ingestion of radioactive substances) can both lead to radiation sickness. Symptoms may not appear immediately and often depend on the dose received.
Clinical Features
The severity and timing of symptoms are dose-dependent. Acute radiation syndrome generally presents in three major patterns:
Mechanism of Action
Radiation damages cells by directly disrupting DNA or indirectly generating free radicals that injure cellular structures. Different types of radiation vary in penetration: alpha particles have low penetration and are mainly harmful if ingested or inhaled, while gamma rays and X-rays penetrate deeply into tissues.
Management
Treatment is largely supportive. Immediate steps include removal from the radiation source and decontamination if necessary. Supportive care may involve intravenous fluids, antiemetics, and management of infections. In cases of bone marrow suppression, growth factors may be used to stimulate blood cell production.
Key Points
Source
Radiation exposure can occur in medical settings (e.g., imaging and cancer therapy), research environments, industrial operations, and nuclear incidents. Radioactive materials are also used in energy production and, in rare cases, weaponized forms.
Typical Presentation
Exposure may be accidental, occupational, or intentional. Large-scale incidents (such as nuclear accidents) or isolated exposures (such as ingestion of radioactive substances) can both lead to radiation sickness. Symptoms may not appear immediately and often depend on the dose received.
Clinical Features
The severity and timing of symptoms are dose-dependent. Acute radiation syndrome generally presents in three major patterns:
- Hematopoietic syndrome: Characterized by bone marrow suppression, leading to reduced blood cell production, anemia, and increased infection risk.
- Gastrointestinal syndrome: Includes nausea, vomiting, diarrhea, and abdominal pain due to damage to the intestinal lining.
- Neurovascular syndrome: Occurs with very high doses and presents with headache, dizziness, confusion, and rapid neurological decline.
Mechanism of Action
Radiation damages cells by directly disrupting DNA or indirectly generating free radicals that injure cellular structures. Different types of radiation vary in penetration: alpha particles have low penetration and are mainly harmful if ingested or inhaled, while gamma rays and X-rays penetrate deeply into tissues.
Management
Treatment is largely supportive. Immediate steps include removal from the radiation source and decontamination if necessary. Supportive care may involve intravenous fluids, antiemetics, and management of infections. In cases of bone marrow suppression, growth factors may be used to stimulate blood cell production.
Key Points
- Clinical severity depends on radiation dose and duration of exposure.
- Early decline in lymphocyte count can help estimate severity and prognosis.
- Alpha radiation is dangerous mainly when internalized, while gamma radiation penetrates deeply.
- Long-term risks include malignancy and organ damage.
- Published on
Toxicology – Irritant Gases (High Water Solubility)
Source
High-solubility irritant gases include ammonia (found in fertilizers and cleaning agents), formaldehyde (used in embalming fluid), hydrogen chloride (metal cleaners), sulfur dioxide (volcanic emissions), and chloramine gas, which forms when ammonia is mixed with bleach.
Typical Presentation
Exposure usually occurs in enclosed environments such as homes or workplaces. Symptoms begin immediately due to strong irritation of the upper airways, often prompting rapid withdrawal from the exposure source.
Clinical Features
Upper respiratory tract irritation predominates. Patients commonly present with eye irritation (conjunctivitis), nasal inflammation (rhinitis), and throat irritation (pharyngitis). More severe exposure can lead to airway swelling, hoarseness (dysphonia), stridor, laryngospasm, and breathing difficulty. In extreme cases, lower respiratory involvement and acute lung injury may occur.
Mechanism of Action
These gases readily dissolve in water and react with moisture on mucosal surfaces. This leads to formation of corrosive compounds such as ammonium hydroxide (from ammonia), hydrochloric acid (from hydrogen chloride), and sulfuric acid (from sulfur dioxide). These substances cause direct tissue injury, often resulting in localized necrosis.
Management
Immediate removal from the exposure source is essential. Treatment includes administration of high-flow oxygen and supportive airway management. Patients should be closely monitored for airway compromise. Severe exposures may require advanced respiratory support and management of lung injury. No specific antidotes are available.
Key Points
Source
High-solubility irritant gases include ammonia (found in fertilizers and cleaning agents), formaldehyde (used in embalming fluid), hydrogen chloride (metal cleaners), sulfur dioxide (volcanic emissions), and chloramine gas, which forms when ammonia is mixed with bleach.
Typical Presentation
Exposure usually occurs in enclosed environments such as homes or workplaces. Symptoms begin immediately due to strong irritation of the upper airways, often prompting rapid withdrawal from the exposure source.
Clinical Features
Upper respiratory tract irritation predominates. Patients commonly present with eye irritation (conjunctivitis), nasal inflammation (rhinitis), and throat irritation (pharyngitis). More severe exposure can lead to airway swelling, hoarseness (dysphonia), stridor, laryngospasm, and breathing difficulty. In extreme cases, lower respiratory involvement and acute lung injury may occur.
Mechanism of Action
These gases readily dissolve in water and react with moisture on mucosal surfaces. This leads to formation of corrosive compounds such as ammonium hydroxide (from ammonia), hydrochloric acid (from hydrogen chloride), and sulfuric acid (from sulfur dioxide). These substances cause direct tissue injury, often resulting in localized necrosis.
Management
Immediate removal from the exposure source is essential. Treatment includes administration of high-flow oxygen and supportive airway management. Patients should be closely monitored for airway compromise. Severe exposures may require advanced respiratory support and management of lung injury. No specific antidotes are available.
Key Points
- Symptoms occur immediately due to high water solubility.
- Upper airway involvement is more prominent than lower airway injury.
- Irritation is often severe enough to limit prolonged exposure.
- Airway monitoring is critical in moderate to severe cases.
